

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/964,992
Filing Date	September 26, 2001
First Named Inventor	Saltveit, Mikal E.
Art Unit	1645
Examiner Name	Baum, Stuart
Attorney Docket Number	02307O-124510US

RECEIVED

MAR 04 2003

TECH CENTER 600/2900

Total Number of Pages in This Submission

9

## ENCLOSURES (Check all that apply)

☐ Fee Transmittal Form

☐ Fee Attached

☒ Amendment / Reply

☐ After Final

☐ Affidavits/declaration(s)

☐ Extension of Time Request

☐ Express Abandonment Request

☐ Information Disclosure Statement

☐ Certified Copy of Priority Document(s)

☐ Response to Missing Parts/ Incomplete Application

☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

☐ Drawing(s)

☐ Licensing-related Papers

☐ Petition

☐ Petition to Convert to a Provisional Application

☐ Power of Attorney, Revocation Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s)

☐ After Allowance Communication to Group

☐ Appeal Communication to Board of Appeals and Interferences

☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☒ Other Enclosure(s) (please identify below)

Amendment in Response to Restriction (6pp); Return Postcard

Remarks

The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual

Townsend and Townsend and Crew LLP  
Kevin Bastian

Reg. No. 34.774

Signature

Date

February 21, 2003

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: February 21, 2003

Typed or printed

Stephanie J. Whitehurst


Signature

Date

February 21, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

On February 21, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: Stephanie J. Whitehurst

#17  
Electron  
Ondt  
PATENT

Attorney Docket No.: 023070-124510US  
Client Ref. No.: 2001-075-2

RECEIVED

MAR 04 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SALTVEIT, *et al.*

Application No.: 09/964,992

Filed: September 26, 2001

For: CHARACTERIZATION OF  
PHENYLALANINE AMMONIA-LYASE  
(PAL) GENE IN WOUNDED LETTUCE  
TISSUE

Examiner: Baum, Stuart

Art Unit: 1645

AMENDMENT AND RESPONSE TO  
RESTRICTION

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action mailed January 24, 2003, please amend the above-identified application as follows:

IN THE CLAIMS:

Please cancel claims 6-8, 14, and 21-23. Please amend claims 1, 2, 4, 9, 11, 12 and 15 to read as follows:

1. An isolated nucleic acid comprising a nucleotide sequence or a fragment thereof encoding the amino acid sequence set forth in SEQ ID NO:1.